To evaluate the ability of NPs formulation to cross the BBB and accumulate in the brain of mice bearing orthotopic tumors, mice were intra-cranially injected with U373MG-LUC and two weeks after tumor cell injection, treated with FITC/TRITC-double labelled NPs-ZOL or NPs-ZOL-Tf, given i.v. at 20 μg/mouse. This evidence concerns the gene TF and neoplasm.